Source-grounded facts extracted from Trans American Aquaculture, Inc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Trans American Aquaculture, Inc issued warrant to purchase up to 243,750,000 shares of Common Stock of warrant to GHS Investments LLC for exercise price of $0.000161 per share.
“the Company issued to GHS a warrant to purchase up to 243,750,000 shares of Common Stock at an exercise price of $0.000161 per share”
Equity Issuances
Trans American Aquaculture, Inc issued six shares of Series D Preferred Stock as commitment shares of preferred stock to GHS Investments LLC.
“GHS purchased 59 shares of Series D Preferred Stock and was issued an additional six shares of Series D Preferred Stock as commitment shares”
Equity Issuances
Trans American Aquaculture, Inc issued fifty-nine (59) shares of Series D Preferred Stock of preferred stock to GHS Investments LLC for purchase price of $1,000 per share, for an aggregate purchase price of $59,000.
“Investments LLC (“ GHS ”) pursuant to which the Company agreed to sell to GHS, at the initial closing, fifty-nine (59) shares of Series D Preferred Stock at a purchase price of $1,000 per share, for an aggregate purchase price of $59,000 (with $3,000 in legal fees reimbursable to GHS, which may be paid in cash or in shares of Series D Preferred Stock). Each”
Material Agreements
Trans American Aquaculture, Inc entered into Securities Purchase Agreement with GHS Investments LLC valued at $59,000 (effective 2026-03-26).
“On March 26, 2026, Trans American Aquaculture, Inc., a Colorado corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ SPA ”) with GHS Investments LLC (“ GHS ”) pursuant to which the Company agreed to sell to GHS, at the initial closing, fifty-nine (59) shares of Series D Preferred Stock at a purchase price of $1,000 per share, for an aggregate purchase price of $59,000”
Equity Issuances
Trans American Aquaculture, Inc issued 19 shares of Series D Preferred Stock (with three shares issued to cover legal fees) and was issued an additional six shares of Series D Preferred Stock as comm of preferred stock to GHS Investments LLC for $1,000 for each share of Series D Preferred Stock and deducting $3,000 in legal fees.
“GHS Investments LLC (“ GHS ”) pursuant to which the Company may sell to GHS up to an aggregate of 63 shares of Series D Preferred Stock for an aggregate of up to $60,000 ($1,000 for each share of Series D Preferred Stock and deducting $3,000 in legal fees which may be issued in shares of Series D Preferred Stock). At the initial closing on September 18,”
Auditor Changes
Trans American Aquaculture, Inc engaged Boladale Lawal & Co. as its auditor.
“On June 26, 2025, through unanimous written consent, the Board approved the engagement of Boladale Lawal & Co. (the “ New Accounting Firm ”) as the Company’s independent registered public accounting firm for the year ended December 31, 2024.”
Auditor Changes
Trans American Aquaculture, Inc dismissed Burton, McCumber & Longoria, LLP as its auditor.
“Trans American Aquaculture, Inc., a Colorado corporation (the “ Company ”), has dismissed Burton, McCumber & Longoria, LLP (the “ Former Accounting Firm ”) as its independent registered public accounting firm, effective as of June 26, 2025.”
Malcolm McNeill resigned as Chief Financial Officer at Trans American Aquaculture, Inc.
“the resignation of Malcolm McNeill”
Adam Thomas was appointed as Chief Financial Officer and Principal Financial and Accounting Officer at Trans American Aquaculture, Inc.
“On August 16, 2024, the board of directors of Trans American Aquaculture, Inc., a Colorado corporation (the “ Company ”), approved the appointment of Adam Thomas (the Company’s current Chief Executive Officer) as the Company’s Chief Financial Officer and Principal Financial and Accounting Officer to fill the position vacated by the resignation of Malcolm McNeill”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.